News|Articles|December 15, 2023

Infectious Disease This Week

In the news this week, the FDA approved the antifungal, isavuconazonium sulfate, which is indicated for children as young as 1 year of age; the continued clinical usefulness of doxycycline; examining infectious disease consults in gram-negative bacteremia; and a clinician utilizes mobile clinics to bring care to marginalized populations.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Latest CME

Virtual Event

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

2-Part Webinar Series

$(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York$

Infectious Disease This Week

Related Content

Cyclosporiasis: When to Seek Medical Care, Duration of Illness, and Preventive Measures

New Single-Step Test Nearly Doubles Early Lyme Disease Detection

Antiviral Being Used in Current Ebola Outbreak Advances Through Dual Development Strategy

Cases of Cyclosporiasis Continue to Rise Across 31 States With Michigan Reporting Highest Numbers

Top Infectious Disease News Stories Week of July 5- July 11

Latest CME

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

27th Annual International Lung Cancer Congress®

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Colorado Oncology Society

Kansas Society of Clinical Oncology

Wyoming State Oncology Society

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Arizona Clinical Oncology Society

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

26th Annual International Lung Cancer Congress

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

IgAN Case Files: Real Conversations, Evolving Evidence

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

20th Annual New York Lung Cancers Symposium®

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

ISGIO 2025: Hepatobiliary Cancers

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Advances in™: Lipoprotein(a) as a Target for ASCVD Risk Reduction – Updates for Clinical Practice

Empowering HIV Management: Evidence-Based Prevention and Treatment Strategies

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Burst CME™ in Gaucher Disease: Patient Evaluation and Management

Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

Cases and Conversations™: Optimizing Patient Outcomes in Pediatric/AYA and Adult ALL/LBL With Asparaginase Therapies and Combinations

Retina Updates in Montréal

25th Annual International Congress on the Future of Breast Cancer® West

Wisconsin Association of Hematology and Oncology

Rhode Island Oncology Society

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1)

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Looking Beneath the Surface: Latest Updates in Identifying and Managing Hypercortisolism in Patients with Type 2 Diabetes

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Community Practice Connections™: 16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Empire State Hematology & Oncology Society (New York)

South Carolina Oncology Society

North Carolina Oncology Association

West Virginia Oncology Society

Breaking Down the Rationale for Targeting TROP2 in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2)

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Tennessee Oncology Practice Society

Washington State Medical Oncology Society

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Montana State Oncology Society

24th Annual International Congress on the Future of Breast Cancer® East

Cross-Disease Integration of Immunotherapy Innovations

Optimizing Treatment for Biliary Tract Cancers

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing